PMID- 24824818
OWN - NLM
STAT- MEDLINE
DCOM- 20141028
LR  - 20181202
IS  - 1881-1469 (Electronic)
IS  - 0021-8820 (Linking)
VI  - 67
IP  - 7
DP  - 2014 Jul
TI  - In vitro activity of telavancin compared with vancomycin and linezolid against 
      Gram-positive organisms isolated from cancer patients.
PG  - 505-9
LID - 10.1038/ja.2014.30 [doi]
AB  - Telavancin is a dual action, bactericidal lipoglycopeptide. Its in vitro activity 
      was compared with vancomycin and linezolid against 392 Gram-positive isolates 
      from cancer patients. MIC90 values (mug ml(-1)) for telavancin, vancomycin and 
      linezolid were determined for methicillin-susceptible Staphylococcus aureus 
      (MSSA), methicillin-resistant S. aureus (MRSA), methicillin-susceptible (MS), 
      methicillin-resistant (MR), coagulase-negative staphylococci (CoNS), viridans 
      group streptococci (VGS), Streptococcus pneumoniae, Bacillus species, 
      Corynebacterium species and Micrococcus species. Telavancin had potent activity 
      against beta-hemolytic streptococci and Staphylococcus lugdunensis. Whereas 100% of 
      MRSA and 98% of MSSA had vancomycin MICs ⩾ 1.0 mug ml(-1) (minimum inhibitory 
      concentrations (MICs) at which poor clinical responses have been reported), the 
      highest telavancin MIC was 0.38 mug ml(-1). For CoNS, 95% of MS and 100% of MR 
      isolates had vancomycin MICs ⩾ 1.0 mug ml(-1), whereas the highest telavancin MIC 
      was 0.38 mug ml(-1). Furthermore, 48% of VGS had vancomycin MICs ⩾ 1.0 mug ml(-1), 
      whereas the highest telavancin MIC was 0.064 mug ml(-1). A similar pattern was 
      noticed for S. lugdunensis, Bacillus species, Corynebacterium species and 
      beta-hemolytic streptococci. These data suggest that telavancin and linezolid have 
      potent activity against most Gram-positive organisms that cause infections in 
      cancer patients. Consequently, they may be considered as alternatives to 
      vancomycin, especially in institutions wherein a substantial proportion of 
      infections are caused by organisms with vancomycin MICs ⩾ 1.0 mug ml(-1).
FAU - Rolston, Kenneth 6th
AU  - Rolston K 6th
AD  - 1] Department of Infectious Diseases, Infection Control, and Employee Health; The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of 
      Houston College of Pharmacy, Houston, TX, USA.
FAU - Wang, Weiqun
AU  - Wang W
AD  - University of Houston College of Pharmacy, Houston, TX, USA.
FAU - Nesher, Lior
AU  - Nesher L
AUID- ORCID: 0000000212300428
AD  - Department of Infectious Diseases, Infection Control, and Employee Health; The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Coyle, Elizabeth
AU  - Coyle E
AD  - 1] Department of Infectious Diseases, Infection Control, and Employee Health; The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of 
      Houston College of Pharmacy, Houston, TX, USA.
FAU - Shelburne, Samuel
AU  - Shelburne S
AD  - Department of Infectious Diseases, Infection Control, and Employee Health; The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Prince, Randall A
AU  - Prince RA
AD  - 1] Department of Infectious Diseases, Infection Control, and Employee Health; The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of 
      Houston College of Pharmacy, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140514
PL  - England
TA  - J Antibiot (Tokyo)
JT  - The Journal of antibiotics
JID - 0151115
RN  - 0 (Acetamides)
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Lipoglycopeptides)
RN  - 0 (Oxazolidinones)
RN  - 6Q205EH1VU (Vancomycin)
RN  - ISQ9I6J12J (Linezolid)
RN  - XK134822Z0 (telavancin)
SB  - IM
MH  - Acetamides/*pharmacology
MH  - Aminoglycosides/*pharmacology
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Gram-Positive Bacteria/*drug effects
MH  - Gram-Positive Bacterial Infections/complications/microbiology
MH  - Humans
MH  - Linezolid
MH  - Lipoglycopeptides
MH  - Microbial Sensitivity Tests
MH  - Neoplasms/*microbiology
MH  - Oxazolidinones/*pharmacology
MH  - Vancomycin/*pharmacology
EDAT- 2014/05/16 06:00
MHDA- 2014/10/29 06:00
CRDT- 2014/05/15 06:00
PHST- 2013/09/18 00:00 [received]
PHST- 2013/12/12 00:00 [revised]
PHST- 2014/02/26 00:00 [accepted]
PHST- 2014/05/15 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2014/10/29 06:00 [medline]
AID - ja201430 [pii]
AID - 10.1038/ja.2014.30 [doi]
PST - ppublish
SO  - J Antibiot (Tokyo). 2014 Jul;67(7):505-9. doi: 10.1038/ja.2014.30. Epub 2014 May 
      14.